More than 20 billion dollars worth of biopharmaceuticals are scheduled to go off-patent by 2006. Given the strong political impetus and the development of technological tools that can answer the questions regulatory authorities may raise, it is inevitable that the FDA and EMEA will allow biogeneric or biosimilar products. Even with all the regulato
Beli ebook ini dan dapatkan 1 lagi PERCUMA!
Bahasa Inggeris ● Format PDF ● Halaman-halaman 584 ● ISBN 9781420037937 ● Penerbit CRC Press ● Diterbitkan 2002 ● Muat turun 3 kali ● Mata wang EUR ● ID 5697838 ● Salin perlindungan Adobe DRM
Memerlukan pembaca ebook yang mampu DRM